Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 31.32

+1.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Douglas who wrote (151)	5/3/1997 12:21:00 PM
From: Douglas	of 455

FOUND ANOTHER REFERENCE TO PRO 2000 IN THE 04/21/97 EDITION OF DRUG TOPICS (COPYRIGHT 1997 MEDICAL ECONOMICS PUBLISHING). JUST A SHORT PARAGRAPH STATING THAT A NEW METHOD OF PREVENTING HIV INFECTION MAY BE ARRIVING IN A GEL. THIS LAST WEEK WAS VERY SLOW. NO NEWS ON PROCEPT. SEEMS TO BE HOLDING AT 3/4. FOUND ANOTHER COMPETITIOR, REPROTECT PRODUTS. THE BUSINESS WIRE (04/10/96) SAID: ULTRAFEM INC. ANNOUNCED THAT ITS PRODUCT, BUFFERGEL, A VAGINAL MICROBICIDE FOR THE PREVENTION OF HIV AND OTHER SEXUALLY TRANSMITTED DISEASES, HAS BEEN CLEARED BY THE FOOD AND DRUG ADMINISTRATION (FDA) FOR PHASE I CLINICAL TRIALS. THE TRIALS WILL BE SPONSORED BY HIVNET, A NETWORK FORMED BY THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES THAT SUPPORTS TRIALS FOR VACCINES AND OTHER PREVENTIVE MEASURES TO STOP THE SPREAD OF HIV. BUFFERGEL IS THE FIRST AIDS PREVENTION TECHNOLOGY TO BE CHOSEN BY HIVNET FOR CLINICAL TRIALS. THE COMPANY IS ALSO WORKING WITH REPROTECT,LLC ON A PRODUCT THAT WOULD COMBINE BUFFERGEL AND A FEMININE HYGIENE PRODUCT FOR CONTRACEPTION, PREVENTION OF DISEASES, AND DELIVERY OF VAGINAL DRUG THERAPY TO TREAT YEAST INFECTIONS AND OTHER CONDITIONS. GO TO: reprotect.com A PATTERN SEEMS TO BE DEVELOPING CONCERNING VAGINAL MICROBICIDE: 1. MORE GOVERNMENT FUNDING 2. MOST COMPANIES ARE IN PHASE I CLINICAL TRIALS 3. NONOXYNOL-9 MAY NOT SOLVE THE PROBLEMS 4. MANY COMPANIES ARE WORKING WITH ESTABLISHED FEMINE HYGIENE PRODUCTS TO MARKET THEIR GEL THIS WOULD SEEM TO PUT PROCEPT NEITHER AHEAD NOR BEHIND THE COMPETITION. THE PLAYING FIELD SEEMS TO BE FAIRLY LEVEL. PROCEPT NEEDS MORE POSITIVE NEWS FROM THE PHASE I TRIAL AND THE SECURING OF ADDITIONAL FUNDS. IF ANYONE STILL FOLLOWS PROCEPT, I HAVE A QUESTION: WHEN A COMPANY REGISTERS THE SALE OF STOCK I READ THAT THE SEC HAS WHAT THEY CALL A "QUIET PERIOD" MANDATED WHILE REGISTRATION IS PENDING. THE QUIET PERIOD PROHIBITS A COMPANY FROM ADVERTISING OR PROMOTING IN ANY FASHION. IS THIS CORRECT? JUST WONDERING HOW THIS MAY AFFECT PROCEPT.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next